BR112012001118A2 - formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer - Google Patents
formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncerInfo
- Publication number
- BR112012001118A2 BR112012001118A2 BR112012001118A BR112012001118A BR112012001118A2 BR 112012001118 A2 BR112012001118 A2 BR 112012001118A2 BR 112012001118 A BR112012001118 A BR 112012001118A BR 112012001118 A BR112012001118 A BR 112012001118A BR 112012001118 A2 BR112012001118 A2 BR 112012001118A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxy
- fluorphenyl
- ylpropyl
- dicarboxamide
- methyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22650909P | 2009-07-17 | 2009-07-17 | |
PCT/US2010/042353 WO2011009095A1 (en) | 2009-07-17 | 2010-07-16 | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012001118A2 true BR112012001118A2 (pt) | 2016-02-23 |
Family
ID=42712017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012001118A BR112012001118A2 (pt) | 2009-07-17 | 2010-07-16 | formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer |
Country Status (15)
Country | Link |
---|---|
US (1) | US8673912B2 (pt) |
EP (1) | EP2454238A1 (pt) |
JP (1) | JP2012533570A (pt) |
KR (1) | KR20120051702A (pt) |
CN (1) | CN102510855B (pt) |
AU (1) | AU2010274012A1 (pt) |
BR (1) | BR112012001118A2 (pt) |
CA (1) | CA2768370A1 (pt) |
EA (1) | EA201200144A1 (pt) |
IL (1) | IL217537A0 (pt) |
MX (1) | MX2012000809A (pt) |
NZ (1) | NZ597695A (pt) |
TW (1) | TW201118072A (pt) |
WO (1) | WO2011009095A1 (pt) |
ZA (1) | ZA201200389B (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2210607T3 (da) * | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
WO2010083414A1 (en) | 2009-01-16 | 2010-07-22 | Exelixis, Inc. | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
JP2013522232A (ja) * | 2010-03-12 | 2013-06-13 | エグゼリクシス, インコーポレイテッド | N−[3−フルオロ−4−({6−(メチロキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボサミドの水和結晶性形状 |
NZ607118A (en) | 2010-07-16 | 2015-05-29 | Exelixis Inc | C-met modulator pharmaceutical compositions |
EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
EP4019498A1 (en) | 2011-02-10 | 2022-06-29 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
CN103957915A (zh) | 2011-09-22 | 2014-07-30 | 埃克塞里艾克西斯公司 | 治疗骨质疏松症的方法 |
ES2765013T3 (es) | 2011-10-20 | 2020-06-05 | Exelixis Inc | Procedimiento para preparar derivados de quinolina |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
WO2014145715A1 (en) | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
KR20150138268A (ko) * | 2013-04-04 | 2015-12-09 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 약물 병용요법 |
CA3181899A1 (en) | 2014-02-14 | 2015-08-20 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
CA2956810C (en) | 2014-07-31 | 2022-10-04 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
EP3476835A4 (en) | 2016-05-16 | 2020-01-01 | GB001, Inc. | QUINOLEIN DERIVATIVE CRYSTAL |
AU2019403024A1 (en) * | 2018-12-20 | 2021-07-15 | Merck Sharp & Dohme Llc | Novel crystalline forms of an NRTTI compound |
CN110357814A (zh) * | 2019-07-12 | 2019-10-22 | 上海翔锦生物科技有限公司 | 对甲苯磺酸盐新晶型及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4342935B2 (ja) | 2001-06-22 | 2009-10-14 | 協和発酵キリン株式会社 | 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DK2210607T3 (da) | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
CA2743416A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
-
2010
- 2010-07-16 AU AU2010274012A patent/AU2010274012A1/en not_active Abandoned
- 2010-07-16 NZ NZ597695A patent/NZ597695A/en not_active IP Right Cessation
- 2010-07-16 JP JP2012520827A patent/JP2012533570A/ja active Pending
- 2010-07-16 US US13/384,451 patent/US8673912B2/en active Active
- 2010-07-16 CA CA2768370A patent/CA2768370A1/en not_active Abandoned
- 2010-07-16 EP EP10737177A patent/EP2454238A1/en not_active Withdrawn
- 2010-07-16 WO PCT/US2010/042353 patent/WO2011009095A1/en active Application Filing
- 2010-07-16 TW TW099123569A patent/TW201118072A/zh unknown
- 2010-07-16 MX MX2012000809A patent/MX2012000809A/es not_active Application Discontinuation
- 2010-07-16 EA EA201200144A patent/EA201200144A1/ru unknown
- 2010-07-16 KR KR1020127004144A patent/KR20120051702A/ko not_active Application Discontinuation
- 2010-07-16 BR BR112012001118A patent/BR112012001118A2/pt not_active IP Right Cessation
- 2010-07-16 CN CN201080042037.0A patent/CN102510855B/zh not_active Expired - Fee Related
-
2012
- 2012-01-15 IL IL217537A patent/IL217537A0/en unknown
- 2012-01-18 ZA ZA2012/00389A patent/ZA201200389B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201200144A1 (ru) | 2012-08-30 |
IL217537A0 (en) | 2012-02-29 |
WO2011009095A8 (en) | 2011-03-24 |
US8673912B2 (en) | 2014-03-18 |
MX2012000809A (es) | 2012-03-14 |
CN102510855A (zh) | 2012-06-20 |
KR20120051702A (ko) | 2012-05-22 |
ZA201200389B (en) | 2012-09-26 |
AU2010274012A1 (en) | 2012-02-09 |
CN102510855B (zh) | 2015-11-25 |
CA2768370A1 (en) | 2011-01-20 |
WO2011009095A1 (en) | 2011-01-20 |
TW201118072A (en) | 2011-06-01 |
EP2454238A1 (en) | 2012-05-23 |
NZ597695A (en) | 2014-05-30 |
US20120270872A1 (en) | 2012-10-25 |
JP2012533570A (ja) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012001118A2 (pt) | formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer | |
ZA201206679B (en) | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
FR2960875B1 (fr) | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique | |
RS52754B (en) | MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT | |
IL231378A0 (en) | Prongs of tubes, rings for connecting tissues and methods of supplying and using them | |
BR112015008447A2 (pt) | métodos para tratar câncer | |
NZ712330A (en) | Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide | |
EA201490676A1 (ru) | Способ лечения остеопороза | |
BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
BR112012019176A2 (pt) | peça de vestuário, em particular uma peça de compressão para uso medicinal. | |
BR112013015855A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. | |
BR112013015859A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica | |
EP3628326C0 (en) | METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE | |
BR112013001297A2 (pt) | composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória | |
FR2967674B1 (fr) | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine | |
FR2934265B1 (fr) | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique | |
FR2954943B1 (fr) | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique | |
WO2015148389A3 (en) | Diagnosis of multiple sclerosis in human and animal subjects | |
BR112013015877A2 (pt) | composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. | |
CL2013001643A1 (es) | Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit | |
IL230484A (en) | "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation | |
BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " | |
BR112013006857A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais | |
BR112015006272A2 (pt) | ''uso cosmético, composto, composição cosmética e método de tratamento cosmético'' | |
BR112014013561A2 (pt) | composição farmacêutica útil para o tratamento de um câncer, tumor maligno, tumor benigno e doenças não-malignas, composição útil para a preparação de uma composição farmacêutica, método para o tratamento de um tumor em um paciente, e, método para o tratamento de uma condição da pele de um paciente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |